CO6551750A2 - Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio - Google Patents

Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio

Info

Publication number
CO6551750A2
CO6551750A2 CO11111072A CO11111072A CO6551750A2 CO 6551750 A2 CO6551750 A2 CO 6551750A2 CO 11111072 A CO11111072 A CO 11111072A CO 11111072 A CO11111072 A CO 11111072A CO 6551750 A2 CO6551750 A2 CO 6551750A2
Authority
CO
Colombia
Prior art keywords
dengue virus
vaccine
adjuvant
aluminum
inactivated dengue
Prior art date
Application number
CO11111072A
Other languages
English (en)
Inventor
Benoit Baras
Dirk Gheysen
Isabelle Solange Lucie Knott
Jean Paul Prieels
Jean-Francois Toussanint
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6551750(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6551750A2 publication Critical patent/CO6551750A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente descripción proporciona composiciones inmunogénicas para la prevención y/o tratamiento de enfermedades causadas por el virus del dengue.
CO11111072A 2009-02-17 2011-08-30 Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio CO6551750A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15306009P 2009-02-17 2009-02-17

Publications (1)

Publication Number Publication Date
CO6551750A2 true CO6551750A2 (es) 2012-10-31

Family

ID=42174405

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11111072A CO6551750A2 (es) 2009-02-17 2011-08-30 Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio

Country Status (23)

Country Link
US (2) US9265821B2 (es)
EP (1) EP2398821B1 (es)
JP (2) JP6058266B2 (es)
KR (1) KR101738704B1 (es)
CN (1) CN102395600B (es)
AR (1) AR075437A1 (es)
AU (1) AU2010215595A1 (es)
BR (1) BRPI1011224A2 (es)
CA (1) CA2752809A1 (es)
CL (1) CL2011001993A1 (es)
CO (1) CO6551750A2 (es)
DO (1) DOP2011000268A (es)
ES (1) ES2649020T3 (es)
IL (1) IL214385A (es)
MX (1) MX338898B (es)
NZ (1) NZ700477A (es)
PE (2) PE20151588A1 (es)
PH (1) PH12015501637A1 (es)
SG (2) SG173194A1 (es)
TW (2) TW201517915A (es)
UY (1) UY32457A (es)
WO (1) WO2010094663A1 (es)
ZA (1) ZA201105656B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
RU2013144207A (ru) * 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
EP2714076A1 (en) * 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
AU2017261706A1 (en) 2016-05-10 2018-11-22 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
JP7195147B2 (ja) * 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
RU2761453C2 (ru) * 2016-12-23 2021-12-08 Интервет Интернэшнл Б.В. Комбинированная вакцина для свиней
WO2019051149A1 (en) * 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
CN112601815A (zh) * 2018-08-27 2021-04-02 迈凯恩技术有限公司 使用永生化单核细胞和诱导细胞的抗感染药物、疫苗等的评价方法
CN111150849A (zh) * 2020-04-02 2020-05-15 广州隽沐生物科技股份有限公司 一种组合物及其制备方法及其应用
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
WO2023147342A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
RU2223262C2 (ru) 1998-06-30 2004-02-10 Ом Фарма Новые ацилированные псевдодипептиды, способ их получения и содержащие их фармацевтические композиции
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
JP2002540168A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
WO2000058444A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
BRPI0010612B8 (pt) * 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
EP2290109B1 (en) 2001-05-22 2014-08-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
ES2423663T3 (es) 2005-08-08 2013-09-23 Oregon Health And Science University Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas
JP4828189B2 (ja) * 2005-09-14 2011-11-30 雅美 森山 分泌型ＩｇＡ及びＩｇＧ抗体誘導剤
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination

Also Published As

Publication number Publication date
MX2011008649A (es) 2011-09-06
CN102395600A (zh) 2012-03-28
TW201043245A (en) 2010-12-16
US9265821B2 (en) 2016-02-23
UY32457A (es) 2011-01-31
PE20151588A1 (es) 2015-11-18
NZ700477A (en) 2016-04-29
PH12015501637A1 (en) 2019-12-11
JP6104988B2 (ja) 2017-03-29
WO2010094663A1 (en) 2010-08-26
DOP2011000268A (es) 2012-07-31
PE20110992A1 (es) 2012-02-12
JP2012517979A (ja) 2012-08-09
US20110318407A1 (en) 2011-12-29
JP6058266B2 (ja) 2017-01-11
MX338898B (es) 2016-05-03
AU2010215595A1 (en) 2011-08-25
CA2752809A1 (en) 2010-08-26
SG2014014385A (en) 2014-04-28
IL214385A (en) 2016-11-30
KR101738704B1 (ko) 2017-06-08
EP2398821B1 (en) 2017-08-30
CL2011001993A1 (es) 2012-04-09
IL214385A0 (en) 2011-09-27
JP2015221803A (ja) 2015-12-10
KR20110132379A (ko) 2011-12-07
TWI528972B (zh) 2016-04-11
EP2398821A1 (en) 2011-12-28
TW201517915A (zh) 2015-05-16
ES2649020T3 (es) 2018-01-09
AR075437A1 (es) 2011-03-30
US20160120972A1 (en) 2016-05-05
CN102395600B (zh) 2015-03-25
ZA201105656B (en) 2012-04-25
BRPI1011224A2 (pt) 2016-03-15
SG173194A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
PH12017500207B1 (en) Indoles for use in influenza virus infection
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
CR20120025A (es) Antigenos de virus de sincicio respiratorio recombinantes
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CL2011003033A1 (es) Uso de un lipopolisacarido de ochrobactrum intermedium lmg3306 o de una composición que lo comprende para el tratamiento y/o prevencion de sepsis o enfermedades infecciosas; procedimiento para la preparacion del lipopolisacárido; y composicion que comprende el lipopolisacarido.
GB2539148A (en) Vaccine compositions
CL2016000300A1 (es) Métodos terapéuticos
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112018010679A8 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
AR052639A1 (es) Composicion vacunal contra el virus de la hepatitis c.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.

Legal Events

Date Code Title Description
FC Application refused